Envisagenics, Inc.
Biotechnology company · New York, United States
Envisagenics, Inc. is a biotechnology company headquartered in New York, United States. Its earliest recorded incorporation is in 2014. It has received 4 US government small-business research awards (SBIR/STTR) from health agencies, $4.2 million in total, most recently in 2022. It has reported private securities offerings to the US SEC, most recently $19 million sold in a notice filed in 2021.
Envisagenics at a glance
What does Envisagenics do?
US government research funding
4 SBIR/STTR small-business research awards from US health agencies, $4.2 million in total (2015 to 2022). NIH funding came from the National Cancer Institute, National Institute of General Medical Sciences.
Private fundraising reported to the SEC
3 Form D notices; the most recent reported $19.2 million sold (2021).
Frequently asked questions about Envisagenics
Where is Envisagenics headquartered?
Envisagenics, Inc. is headquartered in New York, United States.
What does Envisagenics do?
Envisagenics, Inc. is a biotechnology company.
When was Envisagenics founded?
The earliest incorporation on record for Envisagenics, Inc. is in 2014, according to public company registers.
Similar companies
- Lexeo Therapeutics, Inc.New York City, New York, United States
- MiNK Therapeutics, Inc.New York City, New York, United States
- IN8BIO, Inc.New York City, New York, United States
- Anavex Life Sciences Corp.New York City, New York, United States
- Brainstorm Cell Therapeutics Inc.New York City, New York, United States
- Bioincept LLCNew York City, New York, United States
- Protara Therapeutics, Inc.New York City, New York, United States
- Ancilia Biosciences, Inc.New York City, New York, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesLast updated 2026-09-25. Data licences